Cargando…
A phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) in advanced biliary tract carcinoma
BACKGROUND: Unresectable biliary tract carcinoma is known to demonstrate a poor prognosis. We conducted a single arm phase II study of LFP therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-dose consecutive (Cisplatin) CDDP) for advanced biliary tract malignancies basically on an outpa...
Autores principales: | Kobayashi, Kazuma, Tsuji, Akihito, Morita, Sojiro, Horimi, Tadashi, Shirasaka, Tetsuhiko, Kanematsu, Takashi |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1483897/ https://www.ncbi.nlm.nih.gov/pubmed/16677397 http://dx.doi.org/10.1186/1471-2407-6-121 |
Ejemplares similares
-
A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP
por: Seike, Junichi, et al.
Publicado: (2011) -
5-FU Metabolism in Cancer and Orally-Administrable 5-FU Drugs
por: Miura, Koh, et al.
Publicado: (2010) -
Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer
por: Rao, S, et al.
Publicado: (2005) -
Advanced topics in LabWindows/CVI
por: Khalid, Shahid F
Publicado: (2002) -
The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour activity.
por: Ohkawa, K., et al.
Publicado: (1988)